Gene-edited immune cells for AML after transplant
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a type of immune cell called gamma-delta T cells in people with acute myeloid leukemia who still have minimal residual disease after a stem cell transplant. The goal is to see if these cells can clear the remaining leukemia cells safely and effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have been diagnosed with acute myeloid leukemia and had a stem cell transplant.
- You have small amounts of leukemia still detectable after transplant.
- You do not have active graft-versus-host disease or active infections.
- You are in generally good health with adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (gamma-delta T cells from a healthy donor) for people with glioblastoma that has come back or gotten worse after standard treatment. It aims to see if these cells can help fight the tumor.
This trial tests whether adjusting a stem cell transplant (allo-HSCT) based on a marker called MRD (minimal residual disease) improves outcomes for people with a high-risk type of acute myeloid leukemia (AML). It's for those who are newly diagnosed, between 16 and 65, and have early remission after 1 or 2 rounds of chemotherapy.
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
This early-phase study tests a gene-editing approach that turns off CD33 in donated blood-forming cells, aiming to make CD33-targeted immunotherapy safer and more effective. It is for adults with AML that came back after an allogeneic (donor) stem-cell transplant.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Hear when a new AML (Acute Myelogenous Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.